Search Results for “aging” – Page 41 – media

First Patient Dosed in Clinical Trial of YOLT-101 for the Treatment of FH

SHANGHAI, April 2, 2024 /PRNewswire/ — YolTech Therapeutics announced that the first patient has been dosed with YOLT-101, the company’s in vivo genome editing candidate being developed as a single dose, potentially curative therapy for Familial Hypercholesterolemia(FH), marking the commencement of an Investigator-Initiated Trial (IIT). Familial Hypercholesterolemia (FH) is a genetic disorder that affects the body’s ability to remove low-density lipoprotein (LDL) cholesterol from the blood. It is characterized by high levels of LDL cholesterol, also known as “bad” cholesterol, which can lead to an increased risk of early heart disease. YOLT-101, developed independently by YolTech, aims to intervene in specific genetic mutations associated with Familial Hypercholesterolemia. Leveraging advanced gene editing technology and lipid nanoparticle (LNP) delivery, YOLT-101 promises to provide effective treatment options for patients. The preclinical data of YOLT-101 indicate that a single dose of the drug resulted in a significant reduction of LDL-C levels lasting nearly two ...
- Source: drugdu
- 133
- April 4, 2024
YolTech Therapeutics to Participate in 2024 Cell & Gene Meeting on the Mediterranean

SHANGHAI, March 27, 2024 /PRNewswire/ — YolTech Therapeutics, a trailblazing biopharmaceutical company specializing in gene editing, is delighted to announce its participation in 2024 Cell & Gene Meeting on the Mediterranean. The event will take place from April 9th to 11th, 2024, at the esteemed Rome Cavalieri, A Waldorf Astoria Hotel, situated at Via Alberto Cadlolo, 101, 00136 Roma RM, Italy. The Cell & Gene Meeting on the Mediterranean stands as the premier conference uniting the ATMP (Advanced Therapy Medicinal Products) community from Europe and beyond. Covering an extensive array of commercialization topics spanning market access, regulatory issues, manufacturing, and financing within the sector, this program boasts expert-led panels, extensive one-on-one partnering capabilities, exclusive networking opportunities, and over 60 dedicated presentations by leading publicly traded and privately held companies in the space. YolTech is poised to make a significant impact at this event, showcasing its pioneering advancements in in vivo ...
- Source: drugdu
- 99
- April 4, 2024
Gilead, Xilio Therapeutics Ink Exclusive Licensing Agreement to Develop Early Phase Tumor-Activated IL-12

Don Tracy, Associate Editor Deal aims to commercialize XTX301 for treating advanced solid tumors by leveraging Xilio’s tumor-activated immuno-oncology therapies. Gilead Sciences and Xilio Therapeutics announced that they have agreed to terms on a licensing agreement regarding XTX301, Xilio’s Phase I tumor-activated IL-12. According to Gilead, the partnership aims to expand the company’s focus in immuno-oncology, leveraging Xilio’s novel tumor-activation platform to improve its therapeutic nature and build a consistent pipeline of tumor-activated molecules. As per the deal, Xilio will receive an upfront payment of $43.5 million, with $30 million in cash and an equity investment of $13.5 million provided by Gilead in common stock. Overall, Xilio will have the opportunity to earn up to $604 million based on specified development, regulatory, and sales-based milestones.1 “Xilio’s novel tumor-activation platform naturally complements Gilead’s clinical development program in difficult-to-treat cancers and expands our focus in immuno-oncology,” said Bill Grossman, MD, PhD, SVP, ...
- Source: drugdu
- 97
- April 3, 2024
Upgraded Syndromic Testing Analyzer Enables Remote Test Results Access

QIAGEN (Venlo, the Netherlands) has released the QIAstat-Dx Analyzer 2.0, including the Software 1.6 upgrade. This represents a significant advancement from the initial QIAstat-Dx Analyzer 1.0, offering enhanced capabilities for the accurate, rapid, and cost-effective identification of complex syndromes. The system, which is designed for laboratory settings, incorporates economical, disposable cartridges that integrate sample preparation with all necessary reagents on board. Leveraging multiplex real-time PCR technology, it can identify and distinguish between various pathogens, delivering results within approximately one hour. Additionally, the system enables the display of cycle threshold (Ct) values and amplification curves, providing deeper analytical insights beyond those achievable with endpoint PCR or alternative methodologies. A key feature of this upgraded system is the introduction of the QIAstat-Dx Operational Module PRO, which is equipped with a 64-bit processor and 4GB of RAM. This enables the Remote Results Application, a pioneering tool in syndromic testing that allows for the ...
- Source: drugdu
- 128
- April 3, 2024
Upgraded Syndromic Testing Analyzer Enables Remote Test Results Access

QIAGEN (Venlo, the Netherlands) has released the QIAstat-Dx Analyzer 2.0, including the Software 1.6 upgrade. This represents a significant advancement from the initial QIAstat-Dx Analyzer 1.0, offering enhanced capabilities for the accurate, rapid, and cost-effective identification of complex syndromes. The system, which is designed for laboratory settings, incorporates economical, disposable cartridges that integrate sample preparation with all necessary reagents on board. Leveraging multiplex real-time PCR technology, it can identify and distinguish between various pathogens, delivering results within approximately one hour. Additionally, the system enables the display of cycle threshold (Ct) values and amplification curves, providing deeper analytical insights beyond those achievable with endpoint PCR or alternative methodologies. A key feature of this upgraded system is the introduction of the QIAstat-Dx Operational Module PRO, which is equipped with a 64-bit processor and 4GB of RAM. This enables the Remote Results Application, a pioneering tool in syndromic testing that allows for the ...
- Source: drugdu
- 101
- April 2, 2024
Cambodia Phar-Med Expo 2024

Organiser: Minh Vi Exhibition & Advertisement Services Co., Ltd. Time:28 – 30 August 2024 address：Diamond Island Phnom Penh Cambodia Exhibition hall: Diamond Island Convention & Exhibition Center Product range: Medical equipment and equipment: medical aid equipment, rehabilitation physiotherapy equipment, medical vehicle, bed, table, medical aid equipment, surgical equipment, preventive medical equipment, examination equipment, monitoring equipment, treatment equipment, inspection and analysis equipment, special surgical equipment, first aid equipment, surgical equipment, diagnostic equipment and supplies, analysis and control, Monitoring equipment, corrective equipment, ophthalmic instruments and equipment, ENT equipment, dental supplies and equipment, radiological medicine equipment, medical reagents and equipment, prosthetics and rehabilitation equipment, medical and health products and equipment, disinfection and sterilization equipment, traction, diagnostic equipment, treatment equipment, inspection and analysis equipment, etc Medical institutions and laboratory technical equipment: laboratory furniture, laboratory automation and accessories, optical instruments and equipment, dressings, wound care materials, catheters, medical experimental analysis and diagnostic instruments, biopharmaceutical instruments, cell biology ...
- Source: drugdu
- 171
- April 2, 2024
University of Liverpool to lead £125m research facility supported by UKRI investment

Set to open in 2032, the RUEDI facility is funded by the UKRI’s recent infrastructure fund worth £388m The University of Liverpool has announced that it will be leading a national research facility worth £125m to drive scientific discovery and advance technologies as part of the UK Research and Innovation’s (UKRI) infrastructure fund worth £388m. The Relativistic Ultrafast Electron Diffraction and Imaging (RUEDI) facility will benefit areas of research including quantum technologies and personalised medicine. The UKRI recently announced five new infrastructure projects with new funding to equip the UK’s research and innovation bases, with an additional £85m for the UKRI’s Digital Research Infrastructure Programme. In collaboration with the University of Liverpool’s Science and Technology Facilities Council and the Rosalind Franklin Institute, the new facility will allow researchers to explore changes in living cells as they happen to develop more personalised treatments for patients in a more renewable and sustainable ...
- Source: drugdu
- 84
- April 1, 2024
Innovent Dosed First Participant in Phase 3 Clinical Study (Neoshot) of IBI310 (Anti-CTLA-4 Monoclonal Antibody) in Combination with Sintilimab for MSI-H/dMMR Colon Cancer Neoadjuvant Therapy

ROCKVILLE, Md. and SUZHOU, China, March 27, 2024 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major diseases, announces that the first participant has been successfully dosed with IBI310 (anti-CTLA-4 monoclonal antibody) in combination with sintilimab (PD-1 inhibitor) in a randomized, controlled, multicenter Phase 3 clinical trial (Neoshot), for resectable MSI-H/dMMR[1] colon cancer (stage cT4 or cN+) neoadjuvant therapy. Neoshot is the first Phase 3 clinical trial (NCT05890742) in China to investigate MSI-H/dMMR colon cancer neoadjuvant immunotherapy. The study will evaluate the safety and efficacy of IBI310 combined with sintilimab for neoadjuvant therapy, compared with adjuvant chemotherapy after radical surgery for MSI-H/dMMR colon cancer. The primary endpoints are pathologic complete response (pCR) rate and event-free survival (EFS). Previously, in a randomized, controlled, multicenter Phase 1b study for neoadjuvant ...
- Source: drugdu
- 130
- April 1, 2024
CPhI North America 2024

Organiser: Informa Markets Time:7 – 9 May 2024 address：1101 Arch Street Philadelphia, PA 19107, Philadelphia PA United States Exhibition hall: Pennsylvania Convention Center Product range: Apis: vitamins, hormones, sulfonamides, antipyretic analgesics, tetracycline, amino acids and their derivatives, chloramphenicol, digestive system drugs, other anti-infective drugs, penicillins, aminoglycosides, lincomycin, cardiovascular system drugs, anti-parasitic diseases drugs, cephalosporins, macrolides, respiratory system drugs, central nervous system drugs, other Western drugs Ingredients Packaging equipment: pharmaceutical machinery, packaging machinery, packaging materials, pharmaceutical production equipment and technology, pharmaceutical packaging equipment, pharmaceutical packaging materials, pharmaceutical production, cleaning, disinfection configuration and laboratory instrument system Pharmaceutical products: various proprietary Chinese medicines, Western medicines, new drugs, various raw materials, chemical pharmaceuticals, pharmaceutical intermediates, biopharmaceuticals, traditional medicines, Chinese medicine, herbs, animal and plant extracts, veterinary drugs, food ingredients and additives, etc About CPhI North America： CPhI North America is the largest and most authoritative pharmaceutical raw materials exhibition in the United States. The World Pharmaceutical ...
- Source: drugdu
- 163
- March 29, 2024
LifeArc provides £750,000 fund for clinical trial to treat neuroferritinopathy

The progressive and incurable brain disorder currently affects approximately 100 patients worldwide LifeArc has announced that it has funded a pivotal clinical trial at the University of Cambridge for £750,000 to re-purpose a UK-licensed medicine to treat the ultra-rare genetic disease neuroferritinopathy. The recently launched DefINe trial aims to stop the progression of the disease with an existing drug known as Ferriprox (deferiprone), manufactured by Chiesi Global Rare Diseases. Affecting approximately 100 patients worldwide, neuroferritinopathy is a progressive and incurable brain disorder caused by changes in a gene that produces the ferritin light chain protein. This change can lead to a build-up of iron in the brain, which can cause severe symptoms such as loss of speech and swallowing. With currently no effective treatments available to treat the condition, the new randomised, placebo-controlled trial aims to reduce the iron accumulation in the brain using Ferriprox, an affordable oral tablet licensed ...
- Source: drugdu
- 125
- March 29, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.